264PPredictive tools in adjuvant breast cancer: What is the standard of evidence supporting their utility? A literature review examining validation of Adjuvant!, Cancermath and NHS Predict

ConclusionsAll 3 predictive tools have under-represented groups in their development cohorts, specifically those under 35& over 65 years old, as well as larger tumours. Validation studies consistently demonstrate worse performance in these groups. However, due to inconsistent methodology in validation studies, quantitating the summary performance within& across tools is difficult. These predictive tools should be used with caution in under-represented populations. More work is required to look at clinical utility of tools as well as their statistical performance.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research